Combined Phase 2B/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating The Efficacy And Safety Of Filgotinib In The Induction And Maintenance Of Remission In Subjects With Moderately To Severely Active Ulcerative Colitis
Principal Investigator(s)
Email for information
Funded by
GENEVA
Research Start Date
Status
Active
These are combined Phase 2B/3, double-blind, randomized, placebo-controlled studies evaluating the efficacy and safety of filgotinib in the induction and maintenance of remission in subjects with moderately to severely active ulcerative colitis.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.